Individualizing Care in HIV:A Critical Review of Treatment Options

Presented by The Johns Hopkins University School of Medicine

Produced in collaboration with ViralEd LLC

Supported by an educational grant from Merck & Co., Inc.

Welcome and Introduction

Moderator: John Bartlett, MD

Discussants: Cal Cohen, MD

Richard Elion, MD

Ian Frank, MD

Accreditation Statement:The Johns Hopkins University School of Medicine

is accredited by the Accreditation Council for Continuing Medical Education to provide continuing

medical education for physicians.

Credit Designation Statement:The Johns Hopkins University School of Medicine designates this

educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the

extent of their participation in the activity.

To obtain CME credit, after viewing this material go to (Insert Link to Medipix module via VE.com)

and click on “CME Post-Test and Evaluation”

This program is made possible through an educational grant from

Merck & Co.

Program Objectives

At the conclusion of this activity the participant should be:

1. more knowledgeable regarding the importance of individualizing ARV therapy;

2. able to explain the role individualizing ARV therapy has in improving treatment outcomes;

3. able to explain and use in clinical settings the skills needed to gather knowledge regarding the patient and establish a trusting relationship that furthers the exchange of information between clinician and patient needed to accomplish individualization of care;

4. able to apply in clinical practice the concepts important in individualizing ARV therapy including considering and weighing the characteristics of the ARV therapy options available and applying this knowledge to the characteristics of the individual patient to arrive at the optimal choice of ARV therapy for that individual.

Course Directors

John Bartlett, MDProfessor of MedicineJohns Hopkins School of MedicineBaltimore, Maryland

Calvin J. Cohen, MD, MSResearch Director, CRI New EnglandClinical Instructor, Harvard Medical SchoolBoston, Massachusetts

Faculty

Richard A. Elion, MDAssociate Professor of Clinical Medicine

George Washington University Medical CenterWashington, DC

Ian Frank, MDAssociate Professor of Medicine,

Director, Antiretroviral Clinical ResearchUniversity of Pennsylvania Philadelphia, Pennsylvania

Full Disclosure Policy Affecting CME Activities

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a sponsor has with the manufacturers of any commercial products discussed in an educational presentation. The disclosures of the faculty for this program can be found on viraled.com and are presented in the following slides:

Disclosures

John Bartlett, MD– Honorarium Agreements: Abbott Labs

– Consulting Agreements: Johnson & Johnson; Pfizer; Tibotec

Cal Cohen, MD– Grant/Research Support: Bristol-Myers Squibb; Gilead; GlaxoSmithKline;

Merck; Pfizer; Tibotec; Tobira

– Speakers' Bureau: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Tobira

– Consulting Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Tobira; Myriad

– Honorarium Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Myriad

Participant DisclosuresRichard Elion, MD

– Grant/Research Support: Gilead Sciences; Bristol-Myers Squibb; Tibotec; GlaxoSmithKline; Tobira; Rapid Pharm

– Consulting Agreements/Speaker Bureau: Gilead Sciences; Bristol-Myers Squibb; Tibotec

– Honorarium: Gilead Sciences; Bristol-Myers Squibb; Tibotec; GlaxoSmithKline

Ian Frank, MD– Grant/Research Support: Merck & Co; Bavarian Nordic– Consulting Agreements: Bristol-Myers Squibb; Pfizer; Gilead Sciences;

Tibotec; Abbott Laboratories– Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb;

GlaxoSmithKline; Pfizer; Gilead Sciences; Tibotec

This presentation will include information on off-label uses of lopinavir/r, atazanavir, raltegravir, maraviroc, and etravirine.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity

of this CME activity.

Individualizing Care Topics

1. When to Start

2. What to Start: ARV Naïve

3. What to Start: ARV Experienced